Title: Role of autologous platelet-rich plasma (PRP) eye drops as monotherapy for the treatment of severe dry eye disease
Author: Dr Rishi Gupta, M.S.
DOI: https://dx.doi.org/10.18535/jmscr/v7i9.129
Abstract
Objective: To evaluate use of autologous platelet-rich plasma (PRP) eye drops for the treatment of severe dry eye disease.
Materials & Method: This is a retrospective study conducted at a tertiary eye care centre. 30 patients with severe dry eye disease (DED) were included in this study. Data obtained from medical records of patients. Following information noted from medical records. Type of dry eye as evaporative DED (EDED) or aqueous deficient DED (ADDED). Following information were noted before treatment with PRP eye drops and on each follow up visits; OSDI score(Subjective symptoms), Corneal Fluorescein Staining (CFS), Tear Film Breakup Time (TBUT) , Tear Meniscus Height (TMH) and Schirmer’s score (SCH 1). Follow up done at 1 week, 1 month, 3 month and final follw up done at 6 months.
Results: Out of 30 cases 19 (63.3 %) were women, and 11 (36.6 %) were men.16 (53.3 %) had EDED, while 14 (46.6%) had ADDED. 6 months of monotherapy with autologous PRP resulted reduction in dry eye symptoms in 28 (93.3 %) cases. CFS decreased in 23 (76.6 %) patients, TBUT improved in 26 (86.6%) patients, tear meniscus height improved in 24 (80.0%) patients and schirmers score improved in 16 (53.3 %) patients.
Conclusion: Autologous PRP is a effective treatment to improve sigh and symptoms of dry eye disease.
